Pibrozelesin

Drug Profile

Pibrozelesin

Alternative Names: DC 113; DC 88A; DUMs; Duocarmycin; KW 2189; Pibrozelesin hydrobromide

Latest Information Update: 01 Feb 2008

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Kyowa Hakko
  • Developer GlaxoSmithKline; Janssen L.P.; Kyowa Hakko
  • Class Cytostatic antibiotics; Small molecules
  • Mechanism of Action DNA inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Cancer; Gastric cancer; Pancreatic cancer; Renal cancer

Most Recent Events

  • 12 Jul 2005 Corixa Corporation has been acquired and merged into GlaxoSmithKline
  • 30 Jan 2001 Coulter Pharmaceutical has been acquired by Corixa Corporation
  • 27 Oct 2000 A phase II study has been added to the Cancer adverse events section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top